MSL
ATRA icon

Mackay Shields LLC’s Atara Biotherapeutics ATRA Stock Holding History

Mackay Shields LLC’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,820
Closed -$653K – 760
2021
Q1 		$653K Sell
1,820
-961
-35% -$425K ﹤0.01% 1130
2020
Q4 		$1.36M Sell
2,781
-564
-17% -$260K 0.01% 987
2020
Q3 		$1.08M Sell
3,345
-516
-13% -$176K 0.01% 1007
2020
Q2 		$1.41M Buy
3,861
+512
+15% +$129K 0.01% 905
2020
Q1 		$713K Buy
3,349
+492
+17% +$156K 0.01% 1052
2019
Q4 		$1.18M Buy
2,857
+164
+6% +$56.5K 0.01% 1036
2019
Q3 		$951K Buy
2,693
+564
+26% +$210K 0.01% 1126
2019
Q2 		$1.07M Buy
2,129
+1,489
+233% +$1.05M 0.01% 1105
2019
Q1 		$636K Buy
640
+20
+3% +$18.6K ﹤0.01% 1122
2018
Q4 		$538K Buy
+620
New +$576K ﹤0.01% 1124
2018
Q3 		– Sell
-536
Closed -$493K – 1136
2018
Q2 		$493K Buy
+536
New +$576K ﹤0.01% 1102

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Mackay Shields LLC's ATRA Position: Q2 2021 in Review

Mackay Shields LLC sold out of Atara Biotherapeutics (ATRA) in Q2 2021, closing a stake of 1,820 shares — an estimated $653K sold.

Mackay Shields LLC first reported a position in ATRA in Q2 2018 and held it in 11 quarters. The position peaked at $1.41M in Q2 2020. 145 funds tracked by Wall St. Rank hold ATRA as of Q2 2021.

  • Mackay Shields LLC reported no remaining Atara Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 1,820 Atara Biotherapeutics shares in Q2 2021, an estimated $653K.
  • Mackay Shields LLC first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 11 quarters.
  • Mackay Shields LLC's Atara Biotherapeutics position peaked at $1.41M in Q2 2020.
  • 145 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.